Skin fibrosis, or Scleroderma, is a condition caused by chronic inflammation and is characterized by an excess of collagen deposition in the dermis, producing a think, rigid, scar-like tissue. Mice injected subcutaneously with bleomycin induces an inflammatory condition causing skin fibrosis. This fibrosis mimics many of the histopathologic and clinical manifestations of Scleroderma in humans, making it an appropriate model for screening compounds designed to treat this condition.
Preclinical Drug Efficacy Studies
Mice (C57BL/6, Male, 8-10 weeks)
Mice are injected with bleomycin (s.c.) for 21-30 days. Body weights are collected 2X/week for the duration of the study. On terminal day, animals are anesthetized with Isoflurane, bled via the retro-orbital sinus and tissues are collected for downstream measures. Compounds are administered according to the study protocol.
Clinical observations, body weight (2X/week), serum assay of cytokines using Luminex XMAP, homogenization of skin and other tissues for the assay of cytokines using ELISA, FFPE remaining tissues for histological and immunohistochemical examination
Smith GP and Chan ESL. (2010) Molecular Pathogenesis of Skin Fibrosis: Insight from Animal Models. Current Rheumatol Rep; 12(1): 26-33.
Yamamoto T, Takagawa S, Katayama I, Nishioka K. Anti-sclerotic effect of transforming growth factor-beta antibody in a mouse model of bleomycin-induced scleroderma (1999) Clin Immunol; 92: 6â€“13.